國立虎尾科技大學 |

Cardio-Oncology = Management of Toxicities in the Era of Immunotherapy /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Cardio-Oncology/ edited by Antonio Russo, Nicola Maurea, Dimitrios Farmakis, Antonio Giordano.
其他題名:	Management of Toxicities in the Era of Immunotherapy /
其他作者:	Giordano, Antonio.
面頁冊數:	XIV, 122 p. 21 illus., 18 illus. in color.online resource. :
Contained By:	Springer Nature eBook
標題:	Internal Medicine. -
電子資源:	https://doi.org/10.1007/978-3-030-97744-3
ISBN:	9783030977443

Cardio-Oncology = Management of Toxicities in the Era of Immunotherapy /
Cardio-OncologyManagement of Toxicities in the Era of Immunotherapy /[electronic resource] :edited by Antonio Russo, Nicola Maurea, Dimitrios Farmakis, Antonio Giordano. - 1st ed. 2022. - XIV, 122 p. 21 illus., 18 illus. in color.online resource. - Current Clinical Pathology,2197-7828. - Current Clinical Pathology,.

1. Background: Immunology and cancer -- 2. Available immunotherapy drugs in oncology -- 3. Immunotherapy adverse events -- 4. Pathophysiology of cardiac toxicity -- 5. Cardiac risk factors for immunotherapy -- 6. Diagnostic methods of cardiac immunotherapy damaging -- 7. Biomarkers of early cardiotoxicity -- 8. Management of Patients with Cardiac Toxicity: the point of view of the cardiologist -- 9. Management of patients with cardiac toxicity: the point of view of the oncologist -- 10. Future perspectives.

The development of immunotherapy in oncology field has revolutionized the prognosis of many types of cancer. The immune checkpoint inhibitors target receptors whose inhibition increases the activity of immune system cells against tumor cells. In recent years, new immunotherapies have been studied and approved in a growing number of tumors including melanoma, non-small cell lung cancer (NSCLC), and renal cell cancer (RCC). This volume provides a complete and updated state-of-art review regarding the management of cardiovascular toxicities from new immunotherapies. The manuscript is divided into different sections starting from the relationship between cancer and immune system to let the reader understand the new molecular concepts under immunotherapy development. Subsequent chapters describe specifically the immunotherapy options in solid tumor treatment and the main features of the immuno-related cardiovascular complications. This volume is written by experts in the oncological and cardiovascular fields and aims to provide to clinicians who approach current cancer patients a useful tool to move through the paths of modern cardio-oncology. An important section would afford the most relevant interventions needed to manage the cardiac events, suggesting how to reduce their impact and effects on oncological outcomes. The text concludes by addressing future perspectives in the cardio-immunology field, discussing many aspects such as the early detection of cardiovascular damage and the potential role of liquid biopsy in new damage-related biomarkers discovery.

ISBN: 9783030977443

Standard No.: 10.1007/978-3-030-97744-3doiSubjects--Topical Terms:

668583
Internal Medicine.

LC Class. No.: RC254-282

Dewey Class. No.: 616.994

Cardio-Oncology = Management of Toxicities in the Era of Immunotherapy /
LDR:03550nam a22004095i 4500 001 1089562
003 DE-He213
005 20220809083351.0
007 cr nn 008mamaa
008 221228s2022 sz | s |||| 0|eng d
020 $a 9783030977443 $9 978-3-030-97744-3
024 7 $a 10.1007/978-3-030-97744-3 $2 doi
035 $a 978-3-030-97744-3
050 4 $a RC254-282
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 616.994 $2 23
245 1 0 $a Cardio-Oncology $h [electronic resource] : $b Management of Toxicities in the Era of Immunotherapy / $c edited by Antonio Russo, Nicola Maurea, Dimitrios Farmakis, Antonio Giordano.
250 $a 1st ed. 2022.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Humana, $c 2022.
300 $a XIV, 122 p. 21 illus., 18 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Current Clinical Pathology, $x 2197-7828
505 0 $a 1. Background: Immunology and cancer -- 2. Available immunotherapy drugs in oncology -- 3. Immunotherapy adverse events -- 4. Pathophysiology of cardiac toxicity -- 5. Cardiac risk factors for immunotherapy -- 6. Diagnostic methods of cardiac immunotherapy damaging -- 7. Biomarkers of early cardiotoxicity -- 8. Management of Patients with Cardiac Toxicity: the point of view of the cardiologist -- 9. Management of patients with cardiac toxicity: the point of view of the oncologist -- 10. Future perspectives.
520 $a The development of immunotherapy in oncology field has revolutionized the prognosis of many types of cancer. The immune checkpoint inhibitors target receptors whose inhibition increases the activity of immune system cells against tumor cells. In recent years, new immunotherapies have been studied and approved in a growing number of tumors including melanoma, non-small cell lung cancer (NSCLC), and renal cell cancer (RCC). This volume provides a complete and updated state-of-art review regarding the management of cardiovascular toxicities from new immunotherapies. The manuscript is divided into different sections starting from the relationship between cancer and immune system to let the reader understand the new molecular concepts under immunotherapy development. Subsequent chapters describe specifically the immunotherapy options in solid tumor treatment and the main features of the immuno-related cardiovascular complications. This volume is written by experts in the oncological and cardiovascular fields and aims to provide to clinicians who approach current cancer patients a useful tool to move through the paths of modern cardio-oncology. An important section would afford the most relevant interventions needed to manage the cardiac events, suggesting how to reduce their impact and effects on oncological outcomes. The text concludes by addressing future perspectives in the cardio-immunology field, discussing many aspects such as the early detection of cardiovascular damage and the potential role of liquid biopsy in new damage-related biomarkers discovery.
650 2 4 $a Internal Medicine. $3 668583
650 0 $a Internal medicine. $3 644638
650 0 $a Pathology. $3 668553
650 0 $a Cardiology. $3 593957
650 0 $a Oncology. $3 593951
700 1 $a Giordano, Antonio. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1110704
700 1 $a Farmakis, Dimitrios. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1396843
700 1 $a Maurea, Nicola. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1396842
700 1 $a Russo, Antonio. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 889000
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783030977436
776 0 8 $i Printed edition: $z 9783030977450
776 0 8 $i Printed edition: $z 9783030977467
830 0 $a Current Clinical Pathology, $x 2197-781X $3 1254599
856 4 0 $u https://doi.org/10.1007/978-3-030-97744-3
912 $a ZDB-2-SME
912 $a ZDB-2-SXM
950 $a Medicine (SpringerNature-11650)
950 $a Medicine (R0) (SpringerNature-43714)